The Misfit Toys of 2026: From Quantum Dreams to Chicken WingsGlobal Report·11 hours agoXNDU+13.03%ABVX+4.62%
Beyond the Mega-Caps: Surviving the Market's Uncategorized FringeGlobal Report·1 day ago, 04:19 AMLPTH+9.96%UPB+2.50%
Biotech Regulatory Clearances and Edge AI Pivots Prompt Capital Reallocation Across US EquitiesGlobal Report·Jul 26 at 04:15 AMBDRX+2.42%MASK0.00%
Inside the Biotech Sector's Recent Clinical Catalyst WaveGlobal Report·Jul 25 at 04:17 AMGENB+7.26%IBRX+9.08%
Flying Cars, Defense Pivots, and the Tech Fringe of 2026Global Report·Jul 25 at 04:13 AMEH+4.86%ACGL-3.26%
The 2026 Biotech Divide: When Generative Biology Meets the FDA WallGlobal Report·Jul 24 at 04:13 AMINM-10.18%TXG+6.71%
Corporate Restructurings and AI Pivots Dominate Mid-2026 Strategic ShiftsGlobal Report·Jul 22 at 04:17 AMCPNG+6.13%GEMI+1.11%
The Silent Rotation: Inside the Moves of 10 Niche Tech and Defense PlayersGlobal Report·Jul 21 at 04:12 AMTWLO+1.43%KTOS+5.22%
Leadership Shakeups and AI Surges: The Week's Niche Market OverhaulGlobal Report·Jul 19 at 04:13 AMWB+1.37%JKS+1.78%
M&A, AI Drug Discovery, and Late-Stage Clinical Readouts Define US Biotech Q2 TrajectoryGlobal Report·Jul 18 at 04:13 AMAMGN0.00%CRSP+1.68%
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026GlobeNewswire·Jun 14 at 09:00 AMUPB+2.50%
